At week 12 , patients receiving fesoterodine 8 mg ( 779 patients ) had significantly greater reductions from baseline in UUI episodes , micturitions , and urgency episodes than patients receiving fesoterodine 4 mg ( 790 ) or placebo ( 386 ) ; diary-dry rate was significantly higher in the fesoterodine 8-mg group vs the fesoterodine 4-mg and placebo groups ( all P < 0.05 ) .